- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 39/095 - Neisseria
Détention brevets de la classe A61K 39/095
Brevets de cette classe: 622
Historique des publications depuis 10 ans
|
63
|
56
|
54
|
44
|
42
|
33
|
35
|
25
|
27
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1700 |
143 |
| Pfizer Inc. | 3363 |
45 |
| Novartis AG | 11257 |
33 |
| Children's Hospital & Research Center at Oakland | 82 |
25 |
| Sanofi Pasteur Inc. | 301 |
15 |
| The Regents of the University of California | 19544 |
12 |
| Serum Institute of India Private Limited | 100 |
12 |
| Wyeth LLC | 669 |
11 |
| Wyeth Holdings LLC | 55 |
11 |
| Griffith University | 154 |
10 |
| Novartis Vaccines And Diagnostics S.R.L. | 39 |
9 |
| MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. | 24 |
9 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2842 |
9 |
| Intravacc B.V. | 33 |
9 |
| The Board of Trustees of the University of Illinois | 2664 |
7 |
| The Corporation of Mercer University | 33 |
7 |
| Sanofi Pasteur | 303 |
7 |
| Centro de Ingenieria Genetica y Biotecnologia | 198 |
6 |
| Immunobiology Limited | 10 |
6 |
| Chengdu Olymvax Biopharmaceutical Co.,Ltd | 12 |
6 |
| Autres propriétaires | 230 |